Bortenat 3.5mg (Generic Velcade) Coventry — Bortezomib Myeloma & Amyloidosis West Midlands UK 2026
Product Name
Bortenat 3.5mg (Generic Velcade) Coventry — Bortezomib for Multiple Myeloma & Amyloidosis | West Midlands, UK 2026
Product Details
Bortenat 3.5mg contains Bortezomib 3.5mg, a proteasome inhibitor used in the treatment of Multiple Myeloma and selected patients with Systemic Light Chain (AL) Amyloidosis. It is also approved for the treatment of Mantle Cell Lymphoma (MCL) in appropriate clinical settings. Bortezomib works by disrupting protein degradation within cancer cells, leading to cancer cell death and helping control disease progression.
At Unnati Pharmax, we export high-quality generic Bortezomib injections manufactured in WHO-GMP-certified Indian facilities to customers in Coventry, West Midlands, UK, and worldwide, subject to local import regulations.
Product Specifications
| Brand Name | Bortenat 3.5mg |
| Generic Name | Bortezomib |
| Strength | 3.5 mg |
| Dosage Form | Lyophilized Powder for Injection |
| Therapeutic Category | Oncology / Hematology |
| Drug Class | Proteasome Inhibitor |
| Indications | Multiple Myeloma, Systemic Light Chain (AL) Amyloidosis, Mantle Cell Lymphoma (MCL) |
| Route of Administration | Intravenous (IV) or Subcutaneous (SC), as prescribed |
| Storage | Store below 25°C in a dry place, protected from light |
| Prescription Required | Yes |
| Manufacturer | Indian WHO-GMP Certified Manufacturer |
| Export Availability | Coventry, West Midlands, UK & International Markets |
Key Features
- Contains Bortezomib 3.5mg
- Generic alternative to Velcade®
- Used for the treatment of Multiple Myeloma
- Also indicated for selected patients with AL Amyloidosis and Mantle Cell Lymphoma
- Available as a sterile lyophilized injection
- Manufactured in WHO-GMP-certified facilities
- Export-quality packaging with strict quality assurance
- Competitive pricing for hospitals, oncology clinics, and distributors
- Secure international shipping from India
- Worldwide export support with documentation and parcel tracking
Industry Update
Bortezomib remains a cornerstone therapy in the treatment of Multiple Myeloma and continues to be widely used in frontline, relapsed, and transplant-eligible treatment regimens. It also plays an important role in the management of selected patients with Systemic Light Chain (AL) Amyloidosis. Recent advances in myeloma treatment include the expanded use of monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and next-generation proteasome inhibitors in combination with bortezomib-based regimens. The growing availability of high-quality generic bortezomib has improved global access to effective cancer treatment while helping reduce treatment costs. Therapy should always be administered and monitored by qualified oncology specialists in accordance with current clinical guidelines.
Coventry's University Hospitals Coventry and Warwickshire (UHCW) — one of England's largest teaching hospital trusts — manages haematological malignancies including myeloma and amyloidosis for Coventry, Warwickshire, and surrounding areas. Coventry's significant South Asian community in Foleshill and Hillfields, alongside a substantial Eastern European community and Coventry University's large international student body, creates diverse haematological cancer demand. Bortenat 3.5mg provides Coventry's myeloma patients with affordable Bortezomib at dramatically reduced cost versus UK private pricing.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does UHCW manage myeloma for Coventry's population and what is its relationship with Birmingham's Centre for Clinical Haematology?
University Hospitals Coventry and Warwickshire NHS Trust — operating University Hospital Coventry and Warwickshire (UHCW) and Hospital of St Cross in Rugby — provides haematological oncology services for a catchment of approximately 500,000 people. UHCW's haematology programme manages standard myeloma treatment locally while maintaining a referral relationship with Birmingham's Centre for Clinical Haematology (CCH) at Queen Elizabeth Hospital for: autologous stem cell transplant (ASCT) — UHCW patients requiring ASCT are referred to CCH Birmingham, the nearest ASCT centre; clinical trial enrolment — some Myeloma XI+ and phase I trials are only open at CCH Birmingham or other designated sites; and complex refractory cases requiring CAR-T or novel agent access. Bortenat 3.5mg at UHCW: subcutaneous administration is the standard — UHCW's haematology day unit administers Bortenat SC on the standard VCD or VRD schedule; UHCW's clinical pharmacists perform antiviral prophylaxis (Aciclovir/Valaciclovir) prescription alongside every Bortenat initiation; and neuropathy grading at every UHCW Bortenat visit follows CTCAE criteria. The Birmingham-Coventry patient journey: Coventry myeloma patients referred to CCH Birmingham for ASCT return to UHCW for Lenalid maintenance prescribing — a smooth pathway that UHCW's haematology maintains through the West Midlands Haematology Network's shared protocols. Bortenat 3.5mg from Unnati Pharmax serves Coventry patients during UHCW NHS prescription processing gaps and for Coventry University's substantial non-EU international student population who develop haematological conditions requiring Bortenat without NHS funding eligibility.
FAQ 2: How does Coventry's automotive industry heritage — once the UK's car manufacturing capital — create specific health patterns in its myeloma population?
Coventry was the heartland of Britain's automotive industry — Jaguar Land Rover (now Tata Motors), Rolls-Royce aero engines, and historically Standard, Triumph, and Rover cars were all made in Coventry's sprawling factories. The decline of British automotive manufacturing from the 1970s-1990s devastated Coventry's working-class communities but left a legacy of occupational exposures that have shaped the health of Coventry's over-60 population now in the myeloma age group. Occupational chemical exposures and myeloma: while myeloma's aetiology is primarily genetic and age-related, specific occupational chemical exposures — benzene (historically used in automotive manufacturing processes), agricultural pesticides, and industrial solvents — have been associated with elevated myeloma risk in epidemiological studies. Coventry's former automotive workers are now in their late 60s-70s — precisely the myeloma peak incidence age — and UHCW's haematology team documents occupational history for all new myeloma diagnoses. Socioeconomic deprivation and myeloma outcomes: Coventry's post-industrial economic decline — significant unemployment and deprivation in Foleshill, Hillfields, and the city's eastern suburbs — means UHCW's myeloma patients include individuals with complex social circumstances affecting Bortenat treatment adherence: transport to UHCW's haematology day unit for twice-weekly injections; employment constraints around treatment schedules; and nutritional factors affecting treatment tolerance. UHCW's social work and patient transport services specifically support Coventry's deprivation-affected myeloma population — and Bortenat 3.5mg from Unnati Pharmax is most relevant for Coventry's self-funding patients (typically from more economically stable backgrounds) rather than the most deprived communities where NHS pathway and social support services are the appropriate framework.
FAQ 3: How does Bortenat 3.5mg treat primary systemic AL amyloidosis at UHCW Coventry?
AL amyloidosis — the most common systemic amyloidosis type — is caused by misfolded monoclonal light chains produced by an abnormal plasma cell clone (the same cells causing myeloma, but typically smaller clone burden). Coventry's UHCW manages AL amyloidosis patients referred from GPs, cardiologists, and nephrologists who identify the classic multi-organ amyloid presentation: unexplained heart failure with preserved ejection fraction and specific echocardiography features (speckled myocardium, diastolic dysfunction); nephrotic syndrome from renal amyloid deposition; peripheral neuropathy; and macroglossia. Bortenat 3.5mg in Coventry's AL amyloidosis: CyBorD (Cyclophosphamide+Bortenat+Dexamethasone) is the standard induction for AL amyloidosis at UHCW — achieving haematological complete response in 30-40% of patients with optimised once-weekly SC Bortenat dosing. UHCW's amyloidosis cardiac monitoring: cardiac amyloidosis dramatically increases treatment risk — patients with NYHA Class III-IV heart failure have high treatment-related mortality; UHCW's cardiology-haematology joint clinic for AL amyloidosis specifically risk-stratifies cardiac function before Bortenat initiation; troponin and NT-proBNP monitoring during treatment detects cardiac amyloid progression or treatment response. The National Amyloidosis Centre (NAC) at Royal Free Hospital London provides specialist oversight for UHCW's complex AL amyloidosis cases — UHCW maintains a referral pathway to London for patients requiring ASCT for AL amyloidosis (where cardiac function permits) or Daratumumab-based therapy (Dara-CyBorD). Bortenat 3.5mg from Unnati Pharmax serves Coventry's self-funding AL amyloidosis patients during treatment gaps.
FAQ 4: What is the peripheral neuropathy management protocol for Bortenat at UHCW — protecting Coventry's myeloma patients?
Peripheral neuropathy (PN) — tingling, numbness, burning pain, and weakness in hands and feet — is Bortenat's most clinically significant chronic toxicity, occurring in up to 30% of patients without careful dose management. UHCW Coventry's PN management protocol follows WMAS (West Midlands Antimicrobial Stewardship) haematology guidelines aligned with national Bortezomib PN management recommendations. Pre-treatment baseline at UHCW: neurological baseline assessment — vibration sense (tuning fork at medial malleolus), ankle jerks, light touch, and pinprick; documentation of pre-existing neuropathy from diabetes (extremely prevalent in Coventry's South Asian community) — diabetic neuropathy significantly worsens Bortenat's PN risk and UHCW specifically flags diabetic Coventry patients for enhanced PN monitoring. Intra-treatment UHCW PN grading at every Bortenat visit: Grade 1 (tingling, no functional impairment) — continue Bortenat; Grade 2 (pain or functional impairment) — reduce Bortenat from twice-weekly to once-weekly; Grade 3 (severe pain or functional impairment) — hold Bortenat until Grade 1 or less, then restart at reduced dose; Grade 4 (paralysis or permanent disability) — permanently discontinue Bortenat. Subcutaneous versus intravenous PN comparison: UHCW's universal SC adoption (from 2013 MMYVIII trial data) has substantially reduced PN rates compared to historical IV administration — SC Bortenat produces Grade 2-3 PN in approximately 6% versus 15% with IV. Vitamin B6 for Bortenat PN: UHCW's pharmacy recommends Pyridoxine (Vitamin B6) supplementation at 50mg daily for Bortenat-treated Coventry patients — modest evidence supports PN symptom reduction; it is available OTC at Coventry's Boots, Superdrug, and health food stores without prescription.
FAQ 5: How does Coventry University's large international student population create unique Bortenat demand patterns?
Coventry University — a post-1992 university with approximately 35,000 students and one of England's highest proportions of international students (approximately 40%, from over 150 countries) — creates a significant population of young adults in Coventry without NHS funding eligibility during their initial UK residency. While haematological malignancies including myeloma are rare in the 18-25 age group that constitutes most university students, specific conditions are relevant: Hodgkin's lymphoma (peak incidence 15-35 years) — Bortenat is used in some relapsed Hodgkin's protocols at UHCW; rare plasma cell dyscrasias in young adults — POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin changes) can affect young adults and involves Bortenat in treatment. For Coventry University international students from Nigeria, India, Pakistan, Malaysia, and China who develop haematological conditions requiring Bortenat — NHS eligibility as a student is available but requires registration; in the initial period, UHCW provides care at international patient rates; Bortenat 3.5mg from Unnati Pharmax at dramatically reduced private cost versus UHCW's international patient pharmacy pricing provides affordable supply. Coventry University's Student Health Centre can facilitate urgent UHCW haematology referral for international students — and Unnati Pharmax's multilingual WhatsApp service provides culturally familiar medication guidance for Coventry's Nigerian, Indian, and Malaysian Bortenat patients in their preferred languages alongside UHCW's clinical management.
Website
Email Id
Contact Number
+91-8265041513
Bortenat-3.5-mg-Generic-Velcade-Coventry
